Poxel S.A

(OTCGREY:PXXLF)

Latest On Poxel S.A (PXXLF):

Date/Time Type Description Signal Details
2023-01-25 12:46 ESTNewsPoxel's metabolic disorder therapies get orphan drug status in EUN/A
2022-10-03 07:15 ESTNewsPoxel kidney disorder therapy gets FDA orphan drug statusN/A
2022-08-08 17:05 ESTNewsPoxel S.A. reports Q2 resultsN/A
2022-05-18 20:14 ESTNewsPoxel reports Q1 resultsN/A
2021-09-23 20:55 ESTNewsPoxel reports 1H resultsN/A
2021-04-21 12:42 ESTNewsPoxel S.A. reports Q1 resultsN/A
2021-03-25 07:56 ESTNewsPoxel S.A. reports FY resultsN/A
2021-01-15 05:59 ESTNewsPoxel terminates agreement with Metavant for diabetic treatment ImegliminN/A
2020-12-04 06:26 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 00:46 ESTFinancialsCompany financials have been released.Neutral
2020-10-21 13:11 ESTNewsPoxel S.A. reports 9M resultsN/A
2020-10-08 21:07 ESTFinancialsCompany financials have been released.Neutral
2020-10-04 15:25 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:38 ESTFinancialsCompany financials have been released.Neutral
2020-09-24 11:54 ESTFinancialsCompany financials have been released.Neutral
2020-09-22 12:20 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 09:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 12:43 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 16:26 ESTFinancialsCompany financials have been released.Neutral
2020-08-04 19:42 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 12:06 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 04:33 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 20:42 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 08:30 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 00:49 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 16:10 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 16:24 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 21:14 ESTFinancialsCompany financials have been released.Neutral
2020-07-22 12:26 ESTNewsPoxel S.A. reports 1H resultsN/A
2020-07-09 12:34 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 07:33 ESTFinancialsCompany financials have been released.Neutral
2020-07-02 23:37 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 20:13 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 04:05 ESTFinancialsCompany financials have been released.Neutral
2020-06-25 07:27 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 16:04 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 08:15 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 09:49 ESTFinancialsCompany financials have been released.Neutral
2020-06-07 19:49 ESTFinancialsCompany financials have been released.Neutral
2020-06-05 15:35 ESTFinancialsCompany financials have been released.Neutral
2020-06-03 19:26 ESTFinancialsCompany financials have been released.Neutral
2020-05-27 08:53 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 04:39 ESTFinancialsCompany financials have been released.Neutral
2020-05-14 03:54 ESTFinancialsCompany financials have been released.Neutral
2020-05-07 11:37 ESTFinancialsCompany financials have been released.Neutral
2020-05-07 03:55 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 09:17 ESTFinancialsCompany financials have been released.Neutral
2020-05-02 23:44 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 20:03 ESTFinancialsCompany financials have been released.Neutral
2020-04-30 07:31 ESTFinancialsCompany financials have been released.Neutral

About Poxel S.A (PXXLF):

Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.

See Advanced Chart

General

  • Name Poxel S.A
  • Symbol PXXLF
  • Type Common Stock
  • Exchange OTCGREY
  • Currency USD
  • Country USA
  • Full Time Employees 51
  • Fiscal Year EndDecember
  • Web URLhttp://www.poxelpharma.com
View More

Financials

  • Most Recent Quarter 2020-06-30
  • Profit Margin -203%
  • Return on Assets -20%
  • Return on Equity -58%
  • Revenue Per Share $0
  • Gross Profit 26.56 million
  • Quarterly Earnings Growth -66.8%
View More

Highlights

  • Market Capitalization 200.69 million
  • Book Value Per Share $1.92
View More

Share Statistics

  • Shares Outstanding 24.09 million
  • Shares Float 23.93 million
  • % Held by Insiders 1035%
  • % Held by Institutions 30.75%
View More

Technicals

  • Beta 1.8
  • 52 Week High $9.25
  • 52 Week Low $6.03
  • 50 Day Moving Average 8.17
  • 200 Day Moving Average 7.88
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Poxel S.A (PXXLF) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Poxel S.A (PXXLF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-03-312020-06-30$N/A-$0.26$0.00
2019-12-312020-03-31$1.69 million-$0.25$0.00
2019-09-302019-12-31$1.69 million-$0.43$0.00
2019-06-302019-09-30$11.58 million-$0.42$0.00
2019-03-312019-06-30$11.58 million-$0.22$0.00
2018-12-312019-03-31$18.57 million-$0.21$0.00
2018-09-302018-12-31$18.57 million-$0.13$0.00
2018-06-302018-09-30$18.73 million-$0.14$0.00
2018-03-312018-06-30$18.73 million$0.16$0.00
2017-12-312018-03-31$2.65 million$0.17$0.00
2017-09-302017-12-31$2.65 million-$0.33$0.00
2017-06-302017-09-30$N/A-$0.32$0.00
2017-03-312017-06-30$N/A-$0.24$0.00
2016-12-312017-03-31-$0.22$0.00
2016-09-302016-12-31-$0.28$0.00
2016-06-302016-09-30-$0.30$0.00
2016-03-312016-06-30-$0.35$0.00
2015-12-312016-03-31-$0.36$0.00
2015-09-302015-12-31-$0.20$0.00
2015-06-302015-09-30-$0.21$0.00
2015-03-312015-06-30-$0.16$0.00
2014-12-312015-03-31-$0.17$0.00
2014-09-302014-12-31-$0.17$0.00
2014-06-302014-09-30-$0.17$0.00
2014-03-312014-06-30-$0.92$0.00
2013-12-312014-03-31-$0.93$0.00
2013-09-302013-12-31-$1.51$0.00
2013-06-302013-09-30-$1.48$0.00
2013-03-312013-06-30-$0.28$0.00
2012-12-312013-03-31-$0.28$0.00

Poxel S.A (PXXLF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Poxel S.A (PXXLF) Chart:

Poxel S.A (PXXLF) News:

Below you will find a list of latest news for Poxel S.A (PXXLF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Poxel S.A (PXXLF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Poxel S.A (PXXLF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link